Health metrics enabled by wearables are a big untapped opportunity in oncology clinical trials. Especially in chronic cancer such as leukemias, quantitative evidence that a therapeutic improves activity levels, sleep and other measures of quality of life can drive value differentiation and sales growth.
Yet, sponsors of cancer clinical trials have been slower to embrace digital outcome measures than their peers in other therapeutic areas. In this paper, we look at the perceived barriers to the adoption of wearables—and the major benefits that await sponsors that overcome them.
Sponsors of oncology clinical trials that start to adopt wearables will encounter challenges specific to their specialty but early deployments in cancer and the experience in other therapeutic areas show all the problems are manageable. By partnering with a provider that has medical-grade wearables, a flexible technology platform, deep expertise, and a long track record of success, sponsors can work through the complexities of cancer clinical trials to deliver the real-time, real world digital data they need to thrive in the emerging oncology landscape.